Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
First Claim
Patent Images
1. A method for determining whether an agent can be used to reduce the proliferation and /or cause the death of cancer cells or inhibit the growth of a cancer cell population, comprising the steps of:
- a) obtaining a sample of cancer cells;
b) determining and quantifying the level of expression in the cancer cells of a marker identified in Tables 1 and 5; and
c) identifying that an agent can be used to reduce the proliferation and/or cause the death of said cancer cells when the marker is expressed at a certain level.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention identifies and quantifies changes in gene expression associated with non-small cell lung cancer NSCLC by examining gene expression in tissue from normal lung and diseased lung. The present invention also identifies and quantifies expression profiles which serve as useful diagnostic markers as well as markers that are useful to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.
38 Citations
80 Claims
-
1. A method for determining whether an agent can be used to reduce the proliferation and /or cause the death of cancer cells or inhibit the growth of a cancer cell population, comprising the steps of:
- a) obtaining a sample of cancer cells;
b) determining and quantifying the level of expression in the cancer cells of a marker identified in Tables 1 and 5; and
c) identifying that an agent can be used to reduce the proliferation and/or cause the death of said cancer cells when the marker is expressed at a certain level. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- a) obtaining a sample of cancer cells;
-
14. A method for determining whether an agent is effective in treating cancer, comprising the steps of:
- a) obtaining a sample of cancer cells;
b) exposing the sample to an agent;
c) determining and quantifying the level of expression of a marker identified in Tables 1 and 5 in the sample exposed to the agent and in a sample that is not exposed to the agent; and
d) identifying that an agent is effective in treating cancer when expression of the marker is altered in the presence of said agent. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
- a) obtaining a sample of cancer cells;
-
26. The method of claim 26, wherein the agent is cisplatin.
-
27. A method for determining whether treatment with an agent should be continued in a cancer patient, comprising the steps of:
- a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment with the agent;
b) determining and quantifying the level of expression of a marker identified in Tables 1 and 5 in the two or more samples; and
c) continuing treatment when the expression level of the marker is not significantly altered during the course of treatment. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37)
- a) obtaining two or more samples comprising cancer cells from a patient during the course of treatment with the agent;
- 38. The method of claim 38, wherein the agent is a platinum compound.
-
40. A method for identifying new cancer treatments, comprising the steps of:
- a) obtaining a sample of cancer cells;
b) determining and quantifying the level of expression of a marker identified in Tables 1 and 5;
c) exposing the sample to the cancer treatment;
d) determining the level of expression of the marker in the sample exposed to the cancer treatment; and
e) identifying that the cancer treatment is effective in treating cancer when the marker is expressed at a certain level. - View Dependent Claims (41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)
- a) obtaining a sample of cancer cells;
-
53. A method of diagnosing non small cell lung cancer in a patient, comprising:
- (a) detecting and quantifying the level of expression in a tissue sample of c-myc, E2F-1 and p21 genes;
wherein differential expression of the c-myc, E2F-1 and p21 genes is indicative of non small cell lung cancer.
- (a) detecting and quantifying the level of expression in a tissue sample of c-myc, E2F-1 and p21 genes;
-
54. A method of detecting the progression of non small cell lung cancer in a patient, comprising:
- (a) detecting and quantifying the level of expression in a tissue sample of two or more c-myc, E2F-1 and p21 genes;
wherein differential expression of the c-myc, E2F-1 and p21 genes is indicative of non small cell lung cancer progression.
- (a) detecting and quantifying the level of expression in a tissue sample of two or more c-myc, E2F-1 and p21 genes;
-
55. A method of monitoring the treatment of a patient with non small cell lung cancer, comprising:
- (a) administering a pharmaceutical composition to the patient;
(b) preparing a gene expression profile from a cell or tissue sample from the patient; and
(c) comparing the patient gene expression profile to a gene expression from a cell population selected from the group consisting of normal lung cells, and non small cell lung cancer.
- (a) administering a pharmaceutical composition to the patient;
-
56. A method of treating a patient with non small cell lung cancer, comprising:
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1 and 5 or c-myc, E2F-1 and p21 genes;
(b) preparing an IGEI comprising standardized gene expression values using StaRT-PCR from a cell or tissue sample comprising tumor cells obtained before treatment and another sample obtained after treatment; and
(c) comparing the sample obtained prior to treatment with the sample obtained after treatment.
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1 and 5 or c-myc, E2F-1 and p21 genes;
-
57. A method of screening for an agent capable of modulating the onset or progression of non small cell lung cancer, comprising:
- (a) preparing a first IGEI comprising standardized gene expression values using StaRT-PCR of a cell population comprising non small cell cancer cells, wherein the first IGEI determines the expression level of one or more genes from Tables 1 and 5 or c-myc, E2F-2 and p21 genes;
(b) exposing the cell population to the agent;
(c) preparing second IGEI comprising standardized gene expression values using StaRT-PCR of the agent-exposed cell population; and
(d) comparing the first and second IGEIs.
- (a) preparing a first IGEI comprising standardized gene expression values using StaRT-PCR of a cell population comprising non small cell cancer cells, wherein the first IGEI determines the expression level of one or more genes from Tables 1 and 5 or c-myc, E2F-2 and p21 genes;
-
58. A solid phase hybridization template for measuring, in a standardized fashion, PCR products following standardized quantitative RT-PCR comprising:
-
a) preparing at least one solid phase hybridization template where, for each gene, an oligonucleotide of any length that will bind with specificity to both the competitive template, CT, and native template, NT, is spotted to a filter;
b) identifying a suitable oligonucleotide such that the region between the forward primer (common to both the NT and CT) and the 3′
20 bp of the reverse CT primer is evaluated;
c) attaching an oligonucleotide to a solid support at a previously designated location;
d) amplifying the CT and NT PCR products and hybridizing to the spots of the filter wherein each gene (NT and CT) are amplified separately;
e) pooling the PCR products for hybridization;
f) preparing two oligonucleotide probes, each labeled with a different fluor, for each gene wherein one oligonucleotide is homologous to, and will bind to sequences unique to the NT for a gene that was PCR-amplified such that this oligonucleotide binds to the region of the NT that is not homologous to the CT and is labeled with a different fluor, and wherein the other oligonucleotide is specific to the CT and is labeled with a different fluor such that this other oligonucleotide is homologous to and will bind to CT sequences that span the 3′
end of the reverse primer. - View Dependent Claims (59, 60, 61, 62, 63, 64, 65, 66, 78, 79, 80)
-
-
67. A computer system comprising:
- (a) a database containing information identifying the standardized numerical expression level in units of molecules/106 β
-actin molecules in lung tissue of a set of genes comprising at least two genes in Tables 1 and 5 or c0myc, E2F-1 and p21 genes; and
(b) a user interface to view the information. - View Dependent Claims (68, 69, 70, 71, 72, 73, 74, 75, 76, 77)
- (a) a database containing information identifying the standardized numerical expression level in units of molecules/106 β
Specification